160 related articles for article (PubMed ID: 36206664)
21. A Novel Tri-Functional Liposome Re-Educates "Cold Tumor" and Abrogates Tumor Growth by Synergizing Autophagy Inhibition and PD-L1 Blockade.
Zhou F; Li X; Xue X; Li S; Fan G; Cai Y; Chang Z; Qu J; Liu R
Adv Healthc Mater; 2023 Apr; 12(11):e2202757. PubMed ID: 36652763
[TBL] [Abstract][Full Text] [Related]
22. Effective combination of liposome-targeted chemotherapy and PD-L1 blockade of murine colon cancer.
Gu Z; Da Silva CG; Hao Y; Schomann T; Camps MGM; van der Maaden K; Liu Q; Ossendorp F; Cruz LJ
J Control Release; 2023 Jan; 353():490-506. PubMed ID: 36460179
[TBL] [Abstract][Full Text] [Related]
23. Construction of the systemic anticancer immune environment in tumour-bearing humanized mouse by using liposome-encapsulated anti-programmed death ligand 1 antibody-conjugated progesterone.
Kametani Y; Ito R; Ohshima S; Manabe Y; Ohno Y; Shimizu T; Yamada S; Katano N; Kirigaya D; Ito K; Matsumoto T; Tsuda B; Kashiwagi H; Goto Y; Yasuda A; Maeki M; Tokeshi M; Seki T; Fukase K; Mikami M; Ando K; Ishimoto H; Shiina T
Front Immunol; 2023; 14():1173728. PubMed ID: 37492571
[TBL] [Abstract][Full Text] [Related]
24. Cancer-cell-biomimetic nanoparticles systemically eliminate hypoxia tumors by synergistic chemotherapy and checkpoint blockade immunotherapy.
Yao Y; Chen H; Tan N
Acta Pharm Sin B; 2022 Apr; 12(4):2103-2119. PubMed ID: 35847496
[TBL] [Abstract][Full Text] [Related]
25. Hsc70 promotes anti-tumor immunity by targeting PD-L1 for lysosomal degradation.
Xu X; Xie T; Zhou M; Sun Y; Wang F; Tian Y; Chen Z; Xie Y; Wu R; Cen X; Zhou J; Hou T; Zhang L; Huang C; Zhao Q; Wang D; Xia H
Nat Commun; 2024 May; 15(1):4237. PubMed ID: 38762492
[TBL] [Abstract][Full Text] [Related]
26. Bispecific antibody (HER2 × mPEG) enhances anti-cancer effects by precise targeting and accumulation of mPEGylated liposomes.
Chen IJ; Cheng YA; Ho KW; Lin WW; Cheng KW; Lu YC; Hsieh YC; Huang CC; Chuang CH; Chen FM; Su YC; Roffler SR; Cheng TL
Acta Biomater; 2020 Jul; 111():386-397. PubMed ID: 32417267
[TBL] [Abstract][Full Text] [Related]
27. Reversing tumor immunosuppressive microenvironment via targeting codelivery of CpG ODNs/PD-L1 peptide antagonists to enhance the immune checkpoint blockade-based anti-tumor effect.
Zhang M; Fang Z; Zhang H; Cui M; Wang M; Liu K
Eur J Pharm Sci; 2022 Jan; 168():106044. PubMed ID: 34666183
[TBL] [Abstract][Full Text] [Related]
28. Sensitizing tumors to anti-PD-1 therapy by promoting NK and CD8+ T cells via pharmacological activation of FOXO3.
Chung YM; Khan PP; Wang H; Tsai WB; Qiao Y; Yu B; Larrick JW; Hu MC
J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34887262
[TBL] [Abstract][Full Text] [Related]
29. Phytosterol-loaded CD44 receptor-targeted PEGylated nano-hybrid phyto-liposomes for synergistic chemotherapy.
Gautam M; Thapa RK; Gupta B; Soe ZC; Ou W; Poudel K; Jin SG; Choi HG; Yong CS; Kim JO
Expert Opin Drug Deliv; 2020 Mar; 17(3):423-434. PubMed ID: 32028805
[No Abstract] [Full Text] [Related]
30. In situ immunogenic clearance induced by a combination of photodynamic therapy and rho-kinase inhibition sensitizes immune checkpoint blockade response to elicit systemic antitumor immunity against intraocular melanoma and its metastasis.
Kim S; Kim SA; Nam GH; Hong Y; Kim GB; Choi Y; Lee S; Cho Y; Kwon M; Jeong C; Kim S; Kim IS
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33479026
[TBL] [Abstract][Full Text] [Related]
31. Antimetabolite pemetrexed primes a favorable tumor microenvironment for immune checkpoint blockade therapy.
Lu CS; Lin CW; Chang YH; Chen HY; Chung WC; Lai WY; Ho CC; Wang TH; Chen CY; Yeh CL; Wu S; Wang SP; Yang PC
J Immunother Cancer; 2020 Nov; 8(2):. PubMed ID: 33243934
[TBL] [Abstract][Full Text] [Related]
32. Enhancing Tumor Immunotherapy by Multivalent Anti-PD-L1 Nanobody Assembled via Ferritin Nanocage.
Liu M; Jin D; Yu W; Yu J; Cao K; Cheng J; Zheng X; Wang A; Liu Y
Adv Sci (Weinh); 2024 May; 11(20):e2308248. PubMed ID: 38491904
[TBL] [Abstract][Full Text] [Related]
33. Inhibiting autophagy to boost antitumor immunity with tetramethylpyrazine-loaded and PD-L1-targeting liposomal nanoparticles.
Zhou F; Li X; Jia K; Li F; Xue X; Liu J; Qu J; Liu R
Eur J Pharm Sci; 2023 Nov; 190():106581. PubMed ID: 37696460
[TBL] [Abstract][Full Text] [Related]
34. Sialic acid conjugate-modified liposomal platform modulates immunosuppressive tumor microenvironment in multiple ways for improved immune checkpoint blockade therapy.
Li C; Qiu Q; Gao X; Yan X; Fan C; Luo X; Liu X; Wang S; Lai X; Song Y; Deng Y
J Control Release; 2021 Sep; 337():393-406. PubMed ID: 34171446
[TBL] [Abstract][Full Text] [Related]
35. Synergistic combination of targeted nano-nuclear-reactors and anti-PD-L1 nanobodies evokes persistent T cell immune activation for cancer immunotherapy.
Zhu L; Li J; Guo Z; Kwok HF; Zhao Q
J Nanobiotechnology; 2022 Dec; 20(1):521. PubMed ID: 36496381
[TBL] [Abstract][Full Text] [Related]
36. Anti-tumor effect via passive anti-angiogenesis of PEGylated liposomes encapsulating doxorubicin in drug resistant tumors.
Kibria G; Hatakeyama H; Sato Y; Harashima H
Int J Pharm; 2016 Jul; 509(1-2):178-187. PubMed ID: 27234700
[TBL] [Abstract][Full Text] [Related]
37. Regulation of ROS in myeloid-derived suppressor cells through targeting fatty acid transport protein 2 enhanced anti-PD-L1 tumor immunotherapy.
Adeshakin AO; Liu W; Adeshakin FO; Afolabi LO; Zhang M; Zhang G; Wang L; Li Z; Lin L; Cao Q; Yan D; Wan X
Cell Immunol; 2021 Apr; 362():104286. PubMed ID: 33524739
[TBL] [Abstract][Full Text] [Related]
38. N
Liu Z; Wang T; She Y; Wu K; Gu S; Li L; Dong C; Chen C; Zhou Y
Mol Cancer; 2021 Aug; 20(1):105. PubMed ID: 34416901
[TBL] [Abstract][Full Text] [Related]
39. Upregulation of MHC-I and downregulation of PD-L1 expression by doxorubicin and deferasirox codelivered liposomal nanoparticles for chemoimmunotherapy of melanoma.
Song P; Han X; Zheng R; Yan J; Wu X; Wang Y; Zhang H
Int J Pharm; 2022 Aug; 624():122002. PubMed ID: 35817272
[TBL] [Abstract][Full Text] [Related]
40. Combining PD-L1 inhibitors with immunogenic cell death triggered by chemo-photothermal therapy via a thermosensitive liposome system to stimulate tumor-specific immunological response.
Yu J; He X; Wang Z; Wang Y; Liu S; Li X; Huang Y
Nanoscale; 2021 Aug; 13(30):12966-12978. PubMed ID: 34477780
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]